We discover clinically-relevant biomarkers with single-cell analytics and AI
We aim to improve clinical outcomes and shorten the drug development process by leveraging single-cell technologies and our proprietary AI platform ScaiVision.
Using our cluster-free, unbiased, and highly sensitive AI platform, we have built unique capabilities to discover new clinically-relevant biomarker signatures with diagnostic or stratification potential for clinics in several complex indications.
Scailyte provides a rapid and efficient end-to-end pipeline for extracting relevant biosignatures from single-cell data related to efficacy, toxicity or to the mode of action of therapeutics. These discoveries offer the basis for companion diagnostics and in-vitro diagnostic assay prototypes on common platforms in the clinic.